Ranolazine
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diastolic Heart Failure
Conditions
Diastolic Heart Failure
Trial Timeline
Apr 1, 2010 → Feb 1, 2011
NCT ID
NCT01163734About Ranolazine
Ranolazine is a phase 2 stage product being developed by Gilead Sciences for Diastolic Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT01163734. Target conditions include Diastolic Heart Failure.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02360397 | Phase 2 | Completed |
| NCT02251457 | Phase 1 | Completed |
| NCT01721967 | Approved | Completed |
| NCT01705509 | Pre-clinical | Terminated |
| NCT01804543 | Pre-clinical | UNKNOWN |
| NCT01435174 | Approved | Completed |
| NCT02133352 | Approved | Completed |
| NCT01334203 | Approved | Withdrawn |
| NCT01304095 | Approved | UNKNOWN |
| NCT01174173 | Phase 3 | Completed |
| NCT01163734 | Phase 2 | Completed |
| NCT00644332 | Approved | Completed |
| NCT00091429 | Phase 3 | Completed |
Competing Products
6 competing products in Diastolic Heart Failure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| regadenoson | Astellas Pharma | Approved | 85 |
| Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 52 |
| Valsartan | Novartis | Approved | 85 |
| valsartan | Novartis | Approved | 85 |
| Sitexsentin sodium + Placebo | Pfizer | Phase 2 | 51 |
| Sildenafil + Placebo | Pfizer | Phase 3 | 76 |